Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.

about

Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.

P2860

Q52642770-2339E7D2-4AD8-4C58-BD2F-4A05DF0D1B1A

P2860

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.

Item

http://www.wikidata.org/entity/Q38653318

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.

@en

type

Item

label

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.

@en

prefLabel

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.

@en

P1476

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition

@en

P2093

Aruna S Jaiswal

http://www.w3.org/2001/XMLSchema#string

Dennie Jones

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Williamson

http://www.w3.org/2001/XMLSchema#string

Gayathri Srinivasan

http://www.w3.org/2001/XMLSchema#string

Gurjit Singh Sidhu

http://www.w3.org/2001/XMLSchema#string

Keith Wilcoxen

http://www.w3.org/2001/XMLSchema#string

Nasreen Najmunnisa

http://www.w3.org/2001/XMLSchema#string

P2860

High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma

Germline BAP1 mutations predispose to malignant mesothelioma

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells.

Synthetic lethality: exploiting the addiction of cancer to DNA repair.

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Malignant pleural mesothelioma: an update on diagnosis and treatment options.

Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients.

EEPD1 Rescues Stressed Replication Forks and Maintains Genome Stability by Promoting End Resection and Homologous Recombination Repair.

PARP1 is required for chromosomal translocations.

P2888

s00280-017-3401-y

P304

861-867

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-017-3401-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Thomas J George

Robert Hromas

P577

2017-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090928449

http://www.w3.org/2001/XMLSchema#string

P698

28756516

http://www.w3.org/2001/XMLSchema#string

P932

5608777

http://www.w3.org/2001/XMLSchema#string

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.

about

P2860

P2860

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932